Literature DB >> 25085638

Dramatically changing rates and reasons for hospitalization in multiple sclerosis.

Ruth Ann Marrie1, Lawrence Elliott2, James Marriott2, Michael Cossoy2, James Blanchard2, Aruni Tennakoon2, Nancy Yu2.   

Abstract

OBJECTIVE: We aimed to describe hospitalizations in the multiple sclerosis (MS) population, and to evaluate temporal trends in hospitalizations in the MS population compared to the general population.
METHODS: Using population-based administrative data, we identified 5,797 persons with MS and a matched general population cohort of 28,769 persons. Using general linear models, we evaluated temporal trends in hospitalization rates and length of stay in the 2 populations over the period 1984-2011.
RESULTS: In 1984 the hospitalization rate was 35 per 100 person-years in the MS population and 10.5 in the matched population (relative risk [RR] 3.33; 95% confidence interval: 1.67-6.64). Over the study period hospitalizations declined 75% in the MS population but only 41% in the matched population. The proportion of hospitalizations due to MS declined substantially from 43.4% in 1984 to 7.8% in 2011. The 3 most common non-MS-related reasons for admission in the MS population were diseases of the digestive, genitourinary, and circulatory systems. Admissions for bacterial pneumonia, influenza, urinary tract infections, and pressure ulcers occurred more often in the MS population than in the general population, while admissions for circulatory system disease and neoplasms occurred less often. Older age, male sex, and lower socioeconomic status were associated with increased hospitalization rates for non-MS-related reasons.
CONCLUSIONS: Although hospitalization rates have declined dramatically in the MS population over the last quarter century, they remain higher than in the general population. Admissions for MS-related reasons now constitute only a small proportion of the reasons for hospitalization.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Year:  2014        PMID: 25085638      PMCID: PMC4153848          DOI: 10.1212/WNL.0000000000000753

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Prevalence, expenditures, utilization, and payment for persons with MS in insured populations.

Authors:  G C Pope; C J Urato; E D Kulas; R Kronick; T Gilmer
Journal:  Neurology       Date:  2002-01-08       Impact factor: 9.910

2.  Health care resource utilization in inflammatory bowel disease.

Authors:  Teresa Longobardi; Charles N Bernstein
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-02       Impact factor: 11.382

3.  National estimates of intensive care utilization and costs: Canada and the United States.

Authors:  P Jacobs; T W Noseworthy
Journal:  Crit Care Med       Date:  1990-11       Impact factor: 7.598

4.  Prevalence and incidence of ischemic heart disease in multiple sclerosis: A population-based validation study.

Authors:  Ruth Ann Marrie; Bo N Yu; Stella Leung; Lawrence Elliott; Patricia Caetano; Sharon Warren; Christina Wolfson; Scott B Patten; Lawrence W Svenson; Helen Tremlett; John Fisk; James F Blanchard
Journal:  Mult Scler Relat Disord       Date:  2013-04-02       Impact factor: 4.339

5.  Cancer risk in multiple sclerosis: findings from British Columbia, Canada.

Authors:  Elaine Kingwell; Chris Bajdik; Norm Phillips; Feng Zhu; Joel Oger; Stanley Hashimoto; Helen Tremlett
Journal:  Brain       Date:  2012-06-21       Impact factor: 13.501

6.  Socioeconomic trends in hospitalization for multiple sclerosis.

Authors:  Shivanand P Lad; Christopher H Chapman; Michael Vaninetti; Lawrence Steinman; Ari Green; Maxwell Boakye
Journal:  Neuroepidemiology       Date:  2010-06-15       Impact factor: 3.282

7.  A cross-cultural comparison of critical care delivery: Japan and the United States.

Authors:  Carl A Sirio; Kimitaka Tajimi; Nobuyuki Taenaka; Yoshihito Ujike; Kazufumi Okamoto; Hirotada Katsuya
Journal:  Chest       Date:  2002-02       Impact factor: 9.410

8.  Hospital admission due to infections in multiple sclerosis patients.

Authors:  S Montgomery; J Hillert; S Bahmanyar
Journal:  Eur J Neurol       Date:  2013-03-16       Impact factor: 6.089

9.  Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Authors:  Richard A Rudick; William H Stuart; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Ernst-Wilhelm Radue; Fred D Lublin; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

10.  Vascular disease among hospitalized multiple sclerosis patients.

Authors:  Norrina B Allen; Judith H Lichtman; Hillel W Cohen; Jing Fang; Lawrence M Brass; Michael H Alderman
Journal:  Neuroepidemiology       Date:  2008-04-25       Impact factor: 3.282

View more
  26 in total

1.  Comorbidity increases the risk of hospitalizations in multiple sclerosis.

Authors:  Ruth Ann Marrie; Lawrence Elliott; James Marriott; Michael Cossoy; Aruni Tennakoon; Nancy Yu
Journal:  Neurology       Date:  2014-12-24       Impact factor: 9.910

2.  Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts.

Authors:  Nana Amankwah; Ruth Ann Marrie; Christina Bancej; Rochelle Garner; Douglas G Manuel; Ron Wall; Philippe Finès; Julie Bernier; Karen Tu; Kim Reimer
Journal:  Health Promot Chronic Dis Prev Can       Date:  2017-02       Impact factor: 3.240

3.  Epidemiology of hip fracture in nursing home residents with multiple sclerosis.

Authors:  Tingting Zhang; Andrew R Zullo; Theresa I Shireman; Yoojin Lee; Vincent Mor; Qing Liu; Kevin W McConeghy; Lori Daiello; Douglas P Kiel; Sarah D Berry
Journal:  Disabil Health J       Date:  2018-03-21       Impact factor: 2.554

4.  Immune Response to Seasonal Influenza Vaccine in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Long-term Daclizumab Beta: A Prospective, Open-Label, Single-Arm Study.

Authors:  Lahar Mehta; Kimberly Umans; Gulden Ozen; Randy R Robinson; Jacob Elkins
Journal:  Int J MS Care       Date:  2017 May-Jun

Review 5.  The financial contribution of the multiple sclerosis specialist.

Authors:  Joseph R Berger
Journal:  Neurol Clin Pract       Date:  2017-06

6.  Comorbid disease drives short-term hospitalization outcomes in patients with multiple sclerosis.

Authors:  Adys Mendizabal; Dylan P Thibault; James A Crispo; Adina Paley; Allison W Willis
Journal:  Neurol Clin Pract       Date:  2020-06

7.  The Impact of Psychiatric Comorbidity on Health Care Utilization in Inflammatory Bowel Disease: A Population-based Study.

Authors:  Charles N Bernstein; Carol A Hitchon; Randy Walld; James M Bolton; Lisa M Lix; Renée El-Gabalawy; Jitender Sareen; Alexander Singer; Alan Katz; James Marriott; John D Fisk; Scott B Patten; Ruth Ann Marrie
Journal:  Inflamm Bowel Dis       Date:  2021-08-19       Impact factor: 5.325

Review 8.  Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations.

Authors:  Raffaella Greco; Tobias Alexander; Joachim Burman; Nicoletta Del Papa; Jeska de Vries-Bouwstra; Dominique Farge; Jörg Henes; Majid Kazmi; Kirill Kirgizov; Paolo A Muraro; Elena Ricart; Montserrat Rovira; Riccardo Saccardi; Basil Sharrack; Emilian Snarski; Barbara Withers; Helen Jessop; Claudia Boglione; Ellen Kramer; Manuela Badoglio; Myriam Labopin; Kim Orchard; Selim Corbacioglu; Per Ljungman; Malgorzata Mikulska; Rafael De la Camara; John A Snowden
Journal:  Bone Marrow Transplant       Date:  2021-05-24       Impact factor: 5.483

9.  Decrease in rate of multiple sclerosis-related hospitalizations in Portugal.

Authors:  Marta Pereira; Dimitra Lambrelli; Sreeram V Ramagopalan
Journal:  F1000Res       Date:  2016-06-13

10.  Increasing incidence of anogenital warts with an urban-rural divide among males in Manitoba, Canada, 1990-2011.

Authors:  Laura H Thompson; Zoann Nugent; James F Blanchard; Carla Ens; Bo Nancy Yu
Journal:  BMC Public Health       Date:  2016-03-03       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.